Vice President, Biopharma Partnerships
Sean McEvoy is a results-oriented professional with over 20 years of experience as a business development and commercial team leader in laboratory diagnostics and clinical health sciences. Throughout his career, he has been dedicated to creating organizations that provide innovative diagnostic solutions to support therapeutic development and improve patient outcomes. Sean has a diverse range of skills and experience including: corporate and organizational development, investor relations and funding, strategic alliance management, global partnerships and joint ventures, contracting and service agreements, strategic market assessment, reimbursement strategy, regulatory, and compliance.
In his current role at Amprion, Sean is responsible for leading the development and implementation of a strategic plan for global biopharma partnerships to support clinical research and therapeutic development for neurodegenerative disorders. Before joining Amprion, he established a global business development team at Blueprint Genetics and oversaw the expansion of biopharma programs for rare-inherited disorders. Sean also held various leadership positions at Claritas Genomics, GeneDx, and Athena Diagnostics.
Sean completed his undergraduate education in biological sciences (neuroscience) and philosophy (ethics) at USC in Los Angeles, CA, and continued with his graduate education in neuroscience and pharmacology at OHSU in Portland, OR. Sean has several years of experience in basic science research having been employed as a research assistant at HEDCO Neuroscience (USC) and the Center for Research on Occupational and Environmental Toxicology which was renamed Oregon Institute of Occupational Health Science in 2013 (OHSU).
A pioneer in the science of detecting misfolded proteins, Amprion advances the diagnosis of brain disorders. Our SAAmplify™-ɑSYN Test aids physicians in diagnosing Parkinson’s, Lewy body dementia, and Alzheimer’s with Lewy body variant. We plan to launch more biomarker tests in the future.